^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    albumin-bound paclitaxel

    i
    Other names: ABI007, ABI-007, SNA-001
    Company:
    Generic mfg.
    Drug class:
    Bcl2 inhibitor, Tubulin inhibitor
    Related drugs:
    3d
    Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, OHSU Knight Cancer Institute
    New P2 trial • Combination therapy • Metastases
    |
    gemcitabine • albumin-bound paclitaxel • onvansertib (PCM-075)
    3d
    INTEGRATEIIb: RegoNivo vs Standard of Care Chemotherapy in AGOC (clinicaltrials.gov)
    P3, N=450, Active, not recruiting, Australasian Gastro-Intestinal Trials Group | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Opdivo (nivolumab) • docetaxel • albumin-bound paclitaxel • Stivarga (regorafenib) • irinotecan • Lonsurf (trifluridine/tipiracil)
    5d
    TREBLE: Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=8, Terminated, EQRx International, Inc. | Phase classification: P3b --> P3
    Phase classification • Metastases
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR exon 20 mutation
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • Ameile (aumolertinib)
    5d
    Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer (clinicaltrials.gov)
    P2, N=37, Recruiting, Zhejiang Cancer Hospital
    New P2 trial • Metastases
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel • oxaliplatin • Hansizhuang (serplulimab)
    6d
    Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=83, Recruiting, Chinese PLA General Hospital | Trial primary completion date: Feb 2024 --> Jul 2024
    Trial primary completion date • Metastases
    |
    gemcitabine • AiRuiKa (camrelizumab) • albumin-bound paclitaxel • Sulanda (surufatinib) • Teysuno (gimeracil/oteracil/tegafur)
    6d
    Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=44, Not yet recruiting, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
    New P2 trial
    |
    carboplatin • albumin-bound paclitaxel • pemetrexed • ivonescimab (AK112)
    6d
    LIQUIPANC: Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery (clinicaltrials.gov)
    P3, N=100, Recruiting, Elisabethinen Hospital
    New P3 trial • Liquid biopsy • Surgery • Circulating tumor DNA • Biopsy
    |
    albumin-bound paclitaxel • oxaliplatin • irinotecan
    7d
    Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer (clinicaltrials.gov)
    P1/2, N=20, Recruiting, RenJi Hospital
    New P1/2 trial • Metastases
    |
    cisplatin • Tyvyt (sintilimab) • albumin-bound paclitaxel
    7d
    Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective, observational cohort study (GENESECT study). (PubMed, Cancer)
    Genetic polymorphisms from the pharmacokinetics of gemcitabine did not indicate a significant association with efficacy, but COX-2 polymorphisms involved in tumor cell proliferation might affect OS.
    Observational data • Journal • Metastases
    |
    RRM1 (Ribonucleotide Reductase Catalytic Subunit M1) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2)
    |
    gemcitabine • albumin-bound paclitaxel
    7d
    LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer (clinicaltrials.gov)
    P2, N=74, Recruiting, Fudan University
    New P2 trial • Combination therapy • Metastases
    |
    Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • Halaven (eribulin mesylate)
    7d
    EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P2, N=76, Recruiting, NovoCure GmbH
    New P2 trial • Metastases
    |
    Tecentriq (atezolizumab) • gemcitabine • albumin-bound paclitaxel
    10d
    IL4 receptor targeting enables nab-paclitaxel to enhance reprogramming of M2-type macrophages into M1-like phenotype via ROS-HMGB1-TLR4 axis and inhibition of tumor growth and metastasis. (PubMed, Theranostics)
    IL4R-Abx accumulated at tumors, heightened immune-stimulatory cells while reducing immune-suppressing cells, and hampered tumor growth and metastasis in mice more efficiently than Abx and Ctrl-Abx. These results indicate that IL4R-targeting allows enhancement of M2-macrophage shaping into M1-like phenotype by Abx through the ROS-HMGB1-TLR4 axis, improvement of antitumor immunity, and thereby inhibition of tumor growth and metastasis, presenting a new approach to cancer immunotherapy.
    Journal
    |
    HMGB1 (High Mobility Group Box 1) • TLR4 (Toll Like Receptor 4) • IL4 (Interleukin 4) • IL4R (Interleukin 4 Receptor)
    |
    albumin-bound paclitaxel
    10d
    Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=203, Completed, TransThera Sciences (Nanjing), Inc. | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    albumin-bound paclitaxel • tinengotinib (TT-00420)
    11d
    Evaluation of the efficacy and safety of ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1 in neoadjuvant and conversion therapy for advanced gastric cancer: A study protocol of prospective single-center, randomized controlled and open label clinical trial (RNPLS-01). (PubMed, Heliyon)
    Ethics approval has been obtained from the Ethics Committee at the First Affiliated Hospital (Xijing Hospital) of Air force Military Medical University (KY20232220-F-1). This trial has been registered at the ClinicalTrials.gov: NCT06169410 (registration date: December 5, 2023).
    Journal • Metastases
    |
    KDR (Kinase insert domain receptor)
    |
    albumin-bound paclitaxel • Cyramza (ramucirumab) • lobaplatin (D19466)
    11d
    ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC) (clinicaltrials.gov)
    P1, N=28, Recruiting, ProDa BioTech, LLC | Not yet recruiting --> Recruiting | Initiation date: Dec 2023 --> Sep 2023
    Enrollment open • Trial initiation date • Combination therapy • Metastases
    |
    PKM (Pyruvate Kinase M1/2)
    |
    gemcitabine • albumin-bound paclitaxel
    11d
    Biomarker-driven targeted therapy in patients with recurrent platinum-resistant epithelial ovarian cancer (BRIGHT): protocol for an open-label, multicenter, umbrella study. (PubMed, Int J Gynecol Cancer)
    To evaluate the efficacy and safety of biomarker-driven combinatorial therapies of pamiparib, tislelizumab, bevacizumab, and nab-paclitaxel in platinum-resistant, recurrent ovarian cancer. Recruitment is estimated to be completed by 2024 and results may be published by 2027. ClinicalTrials.gov: NCT05044871.
    Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CD8 (cluster of differentiation 8)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA wild-type
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab) • albumin-bound paclitaxel • Partruvix (pamiparib)
    12d
    Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma (clinicaltrials.gov)
    P2, N=59, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2024 --> Jan 2024
    Enrollment closed • Trial primary completion date • Combination therapy
    |
    gemcitabine • albumin-bound paclitaxel
    12d
    Saltikva for Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Salspera LLC | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • irinotecan • leucovorin calcium • Saltikva (attenuated Salmonella typhimurium expressing IL-2)
    13d
    the Predictive Value of Immune Cell in Locally Advanced Cervical Cancer (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, RenJi Hospital
    New trial • Metastases • Immune cell
    |
    Tyvyt (sintilimab) • albumin-bound paclitaxel
    14d
    A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (clinicaltrials.gov)
    P1, N=282, Recruiting, Amgen | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • cisplatin • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • AMG 193
    14d
    Abequolixron (RGX-104) and Durvalumab in Lung Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, UNC Lineberger Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    carboplatin • Imfinzi (durvalumab) • albumin-bound paclitaxel • pemetrexed • abequolixron (RGX-104)
    16d
    Pembrolizumab Plus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After 5 Years of Follow-Up. (PubMed, J Thorac Oncol)
    P3; With ∼5 years of follow-up, pembrolizumab plus chemotherapy provided clinically meaningful and durable improvements in survival outcomes versus chemotherapy alone in patients with previously untreated metastatic NSCLC with PD-L1 TPS <1%. These results continue to support pembrolizumab plus chemotherapy as a standard of care in this patient population.
    Journal • Retrospective data • Tumor proportion score • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed
    17d
    Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trial. (PubMed, EClinicalMedicine)
    Patients with clinical stage II/III TNBC were treated with 5 cycles of anlotinib (12 mg, d1-14, q3w) plus 6 cycles of taxanes (docetaxel 75 mg/m2 ,d1, q3w or nab-paclitaxel 125 mg/m2, d1 and d8, q3w) and lobaplatin (30 mg/m2, d1, q3w), followed by surgery. The addition of anlotinib to neoadjuvant chemotherapy showed manageable toxicity and encouraging antitumor activity for patients with clinical stage II/III TNBC. Chongqing Talents Project, Chongqing Key Project of Technology Innovation and Application Development and Chongqing Outstanding Youth Natural Science Foundation.
    P2 data • Journal • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • AR (Androgen receptor) • FGFR (Fibroblast Growth Factor Receptor)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative
    |
    docetaxel • Focus V (anlotinib) • albumin-bound paclitaxel • lobaplatin (D19466)
    17d
    Efficacy and biomarker analysis of second-line nab-paclitaxel plus sintilimab in patients with advanced biliary tract cancer. (PubMed, Cancer Sci)
    Nab-paclitaxel plus sintilimab is a potentially effective and tolerable second-line regimen for advanced BTC that deserves to be studied in large-scale trials. PD-L1 status and CD8+ T cell infiltration might be promising biomarkers for efficacy prediction.
    Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
    |
    PD-L1 expression
    |
    Tyvyt (sintilimab) • albumin-bound paclitaxel
    18d
    Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax (clinicaltrials.gov)
    P1, N=43, Recruiting, M.D. Anderson Cancer Center | Suspended --> Recruiting | N=21 --> 43
    Enrollment open • Enrollment change • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Tecentriq (atezolizumab) • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cometriq (cabozantinib capsule)
    18d
    A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=393, Active, not recruiting, Astellas Pharma Global Development, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression
    |
    gemcitabine • albumin-bound paclitaxel • Vyloy (zolbetuximab)
    18d
    Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer (clinicaltrials.gov)
    P2, N=77, Active, not recruiting, Seoul National University Hospital | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium
    18d
    Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P=N/A, N=32, Active, not recruiting, Translational Drug Development | Recruiting --> Active, not recruiting | Phase classification: P2 --> PN/A | Trial completion date: Jun 2024 --> Apr 2025 | Trial primary completion date: Mar 2024 --> Dec 2024
    Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Metastases
    |
    albumin-bound paclitaxel
    19d
    FD-IMPACT: Newly Emerging Immunotherapy for Pancreatic Cancer Treatment (clinicaltrials.gov)
    P1/2, N=117, Not yet recruiting, Fudan University
    New P1/2 trial
    |
    gemcitabine • 5-fluorouracil • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • leucovorin calcium • tifcemalimab (TAB004) • JS007
    19d
    Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer (clinicaltrials.gov)
    P1, N=57, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • albumin-bound paclitaxel • ZEN-3694
    19d
    Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC (clinicaltrials.gov)
    P2, N=67, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial • Metastases
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel
    20d
    Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P=N/A, N=70, Completed, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting --> Completed | Trial completion date: May 2025 --> Dec 2023 | Trial primary completion date: May 2025 --> Dec 2023
    Trial completion • Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • paclitaxel • Tyvyt (sintilimab) • albumin-bound paclitaxel • oxaliplatin
    21d
    Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Platinum-doublet + Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076) (clinicaltrials.gov)
    P3, N=186, Recruiting, Genelux Corporation | Trial primary completion date: Aug 2024 --> Aug 2025
    Trial primary completion date
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pegylated liposomal doxorubicin • olvimulogene nanivacirepvec (GL-ONC1)
    24d
    Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=117, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2024 --> Sep 2024 | Trial primary completion date: Jun 2024 --> Sep 2024
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative
    |
    Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    24d
    A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2/3, N=482, Not yet recruiting, Hutchmed
    New P2/3 trial • Metastases
    |
    gemcitabine • AiRuiKa (camrelizumab) • albumin-bound paclitaxel • Sulanda (surufatinib)
    24d
    NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, OHSU Knight Cancer Institute | Trial primary completion date: Apr 2024 --> Apr 2025
    Trial primary completion date • Surgery • Metastases
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    gemcitabine • capecitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • fluorouracil topical
    25d
    NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=18, Recruiting, TCRCure Biopharma Ltd. | Phase classification: P1/2 --> P1 | Trial primary completion date: Oct 2023 --> Oct 2024
    Phase classification • Trial primary completion date • Metastases
    |
    CTAG1B (Cancer/testis antigen 1B)
    |
    CTAG1B expression
    |
    albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • N201
    25d
    Efficacy and safety of first-line treatment for metastatic triple-negative breast cancer: A network meta-analysis. (PubMed, Cancer Pathog Ther)
    Network meta-analysis results showed that cisplatin combined with nab-paclitaxel or paclitaxel was superior to docetaxel plus capecitabine in terms of PFS and ORR. For PD-L1 and BRCA mutation-positive tumors, atezolizumab/pembrolizumab combined with nab-paclitaxel and talazoparib is an effective treatment option. Neutropenia, diarrhea, and fatigue are frequently occurring serious adverse events.
    Retrospective data • Review • Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Keytruda (pembrolizumab) • cisplatin • Tecentriq (atezolizumab) • docetaxel • Talzenna (talazoparib) • capecitabine • albumin-bound paclitaxel
    25d
    Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial. (PubMed, Gland Surg)
    In this single-arm exploratory phase II trial, patients with treatment-naïve HER2-positive BC (stage IIA-IIIC) received pyrotinib 400 mg once daily and taxanes [docetaxel 75 mg/m2 or nanoparticle albumin-bound (nab)-paclitaxel 260 mg/m2 every 3 weeks, or paclitaxel 80 mg/m2 weekly] for a total of four 21-day cycles before surgery. In female patients with HER2-positive non-metastatic BC, neoadjuvant pyrotinib monotherapy plus taxanes appears to show promising clinical benefit and controllable AEs &lsqb;Chinese Clinical Trial Registry (ChiCTR2100050870)]. The long-term efficacy and safety of this regime warrant further verification.
    P2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • EGFR positive
    |
    docetaxel • Irene (pyrotinib) • albumin-bound paclitaxel
    25d
    PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients (clinicaltrials.gov)
    P2, N=81, Recruiting, Fudan University
    New P2 trial • Surgery • Metastases
    |
    gemcitabine • albumin-bound paclitaxel
    25d
    A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (clinicaltrials.gov)
    P1, N=282, Not yet recruiting, Amgen
    New P1 trial • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • cisplatin • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • AMG 193
    25d
    Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Wuhan Union Hospital, China
    New P2 trial • Metastases
    |
    gemcitabine • albumin-bound paclitaxel • Sulanda (surufatinib)